Dimerix Receives First Development Milestone Payment From Japan Partner

MT Newswires Live
06-30

Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.

DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.

The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.

Shares rose nearly 2% in morning trade Monday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10